Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce W Bode

Showing results (21-30 of 128) with videos related to

Pageof 13
Sort By:
Diabetes Technology & Therapeutics|February 21, 2023
Continuous and Intermittent Glucose Monitoring in 2022Klemen Dovc, Bruce W Bode, Tadej Battelino
Diabetes Technology & Therapeutics|January 31, 2017
An Expert Opinion on Advanced Insulin Pump Use in Youth with Type 1 DiabetesBruce W Bode, Francine R Kaufman, Nan Vint
Diabetes Care|February 22, 2018
Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957Bruce W Bode, Keith Bowering, David Russell-Jones
Postgraduate Medicine|June 4, 2002
Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetesBruce W Bode, William V Tamborlane, Paul C Davidson
The Diabetes Educator|April 22, 2010
Individualizing care for the many: the evolving role of professional continuous glucose monitoring systems in clinical practiceElizabeth A Nardacci, Bruce W Bode, Irl B Hirsch
Diabetes Care|September 28, 2005
Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operationPaul C Davidson, R Dennis Steed, Bruce W Bode
Diabetes Technology & Therapeutics|March 9, 2026
Continuous and Intermittent Glucose Monitoring in 2025Jennifer L Sherr, Bruce W Bode, Tadej Battelino, et al.
The American Journal of Geriatric Pharmacotherapy|November 8, 2011
Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studiesBruce W Bode, Jason Brett, Ali Falahati, et al.
Diabetes Care|September 28, 2005
Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative valuesBruce W Bode, Sherwyn Schwartz, Harrison A Stubbs, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 22, 2005
Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring systemBruce W Bode, R Dennis Steed, Debra S Schleusener, et al.
Pageof 13

Showing results (21-30 of 128) with videos related to

Sort By:
Pageof 13
Diabetes Technology & Therapeutics|February 21, 2023
Continuous and Intermittent Glucose Monitoring in 2022Klemen Dovc, Bruce W Bode, Tadej Battelino
Diabetes Technology & Therapeutics|January 31, 2017
An Expert Opinion on Advanced Insulin Pump Use in Youth with Type 1 DiabetesBruce W Bode, Francine R Kaufman, Nan Vint
Diabetes Care|February 22, 2018
Response to Comment on Russell-Jones et al. Diabetes Care 2017;40:943-950. Comment on Bowering et al. Diabetes Care 2017;40:951-957Bruce W Bode, Keith Bowering, David Russell-Jones
Postgraduate Medicine|June 4, 2002
Insulin pump therapy in the 21st century. Strategies for successful use in adults, adolescents, and children with diabetesBruce W Bode, William V Tamborlane, Paul C Davidson
The Diabetes Educator|April 22, 2010
Individualizing care for the many: the evolving role of professional continuous glucose monitoring systems in clinical practiceElizabeth A Nardacci, Bruce W Bode, Irl B Hirsch
Diabetes Care|September 28, 2005
Glucommander: a computer-directed intravenous insulin system shown to be safe, simple, and effective in 120,618 h of operationPaul C Davidson, R Dennis Steed, Bruce W Bode
Diabetes Technology & Therapeutics|March 9, 2026
Continuous and Intermittent Glucose Monitoring in 2025Jennifer L Sherr, Bruce W Bode, Tadej Battelino, et al.
The American Journal of Geriatric Pharmacotherapy|November 8, 2011
Comparison of the efficacy and tolerability profile of liraglutide, a once-daily human GLP-1 analog, in patients with type 2 diabetes ≥65 and <65 years of age: a pooled analysis from phase III studiesBruce W Bode, Jason Brett, Ali Falahati, et al.
Diabetes Care|September 28, 2005
Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative valuesBruce W Bode, Sherwyn Schwartz, Harrison A Stubbs, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|October 22, 2005
Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring systemBruce W Bode, R Dennis Steed, Debra S Schleusener, et al.
Pageof 13